Insulet (PODD)
(Delayed Data from NSDQ)
$238.80 USD
-0.21 (-0.09%)
Updated Sep 25, 2024 04:00 PM ET
After-Market: $238.75 -0.05 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum C VGM
Brokerage Reports
0 items in cart
Insulet Corporation [PODD]
Reports for Purchase
Showing records 201 - 220 ( 346 total )
Company: Insulet Corporation
Industry: Medical - Products
Neulasta Onpro Kit Enters 2016 with Solid Momentum and Room to Deliver Potential Upside; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Neulasta Onpro Kit Continued to Make Solid Share Gains in November; Now Represents 25% of Neulasta Franchise; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Positive (Albeit Temporary) Implications of a 2-Year Suspension of the Medical Device Tax
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
October Neulasta Onpro Kit Symphony Health Sales Estimate Reflects Continued Solid Share Gains; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Q3 sales beat - could OmniPod diabetes become a means to an end in drug delivery?
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Improving Business Trends Tough To Ignore This Time; Raising PT to $44; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Drug Delivery and International Performing Very Well; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Insulin Pump Project: Historical survey of ~5,700 users, reiterate STRONG BUY
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Ypsomed FY1H16 Results Suggest It Remains On Track To Grow Its OmniPod Installed Base by 40%; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Neulasta On-Body Injector Symphony Health Sales Estimate: September Data Suggests A Return to Solid Share Gains; Maintain OUTPERFORM and $40 PT
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
3Q15 Preview: MedTech Fundamentals Remain Intact Despite Market Volatility
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
3Q15 Preview: MedTech Fundamentals Remain Intact Despite Market Volatility
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Neulasta On Body Injector Symphony Health Sales Estimate
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Neulasta On Body Injector Symphony Health Sales Estimate
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
July Neulasta Sales Suggest Impressive OBI Adoption Representing 22% of Neulasta Franchise; Positive for PODD Drug Delivery; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
July Neulasta Sales Suggest Impressive OBI Adoption Representing 22% of Neulasta Franchise; Positive for PODD Drug Delivery; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Q2 - the mystery of US OmniPod sales versus patient adds; maintain HOLD
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
Despite Some Confusion, The Message That Things Are Improving Is Clear; Raising PT to $40; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Company: Insulet Corporation
Industry: Medical - Products
Q2 results ahead of estimates and survey of 5,500+ pump users (2007 - present)
Provider: Feltl & Company
Analyst: HAYNOR B
Company: Insulet Corporation
Industry: Medical - Products
2Q Beat And Favorable Guidance Suggest PODD Is Regaining Momentum; Historical Accounting Issue Is A Minor Distraction; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.